Comparing of Tocagen Inc. (TOCA) and Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)

Tocagen Inc. (NASDAQ:TOCA) and Ritter Pharmaceuticals Inc. (NASDAQ:RTTR), both competing one another are Biotechnology companies. We will compare their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tocagen Inc. 18.04M 12.69 48.95M -2.02 0.00
Ritter Pharmaceuticals Inc. N/A 0.00 19.41M -3.08 0.00

In table 1 we can see Tocagen Inc. and Ritter Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows Tocagen Inc. and Ritter Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Tocagen Inc. -271.34% 0% 0%
Ritter Pharmaceuticals Inc. 0.00% -135% -86.8%


Tocagen Inc.’s Current Ratio and Quick Ratio are 5.9 and 5.9 respectively. The Current Ratio and Quick Ratio of its competitor Ritter Pharmaceuticals Inc. are 5.1 and 5.1 respectively. Tocagen Inc. therefore has a better chance of paying off short and long-term obligations compared to Ritter Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both Tocagen Inc. and Ritter Pharmaceuticals Inc. are owned by institutional investors at 38.2% and 24.3% respectively. Insiders held roughly 6.59% of Tocagen Inc.’s shares. On the other hand, insiders held about 13.5% of Ritter Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tocagen Inc. 5.82% 3.37% -3.64% 38.74% 4.02% 41.78%
Ritter Pharmaceuticals Inc. 5.89% 10.35% -16.1% -68.84% -73.95% 8.53%

For the past year Tocagen Inc.’s stock price has bigger growth than Ritter Pharmaceuticals Inc.


Tocagen Inc. beats Ritter Pharmaceuticals Inc. on 7 of the 9 factors.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The companyÂ’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing various conditions, including gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.